The epidermal growth factor receptor (EGFR) is a long known, versatile signal transducer that has been well conserved during evolution. It functions in a wide range of cellular processes including cell fate determination, proliferation, cell migration and apoptosis. The activity of the EGFR is subject to modulation by multiple positive and negative regulators and is transduced to the nucleus by several conserved signaling cassettes. Here we will briefly review the hallmarks of EGFRs and their functions as well as summarize some of the mechanisms cells use to modulate EGFR activity.
EGFR structure
The EGFR belongs to the large family of cell surface receptors with intrinsic protein tyrosine kinase (RTK) activity. At the plasma membrane the unstimulated EGFR is present as a monomer. Upon binding of extracellular ligand, the EGFR undergoes dimerization resulting in transautophosphorylation of its cytoplasmic domain.
In vertebrates, four EGFR family members are known: ErbB1, also termed EGFR or HER1; ErbB2, also termed Neu or HER2; ErbB3, or HER3; and ErbB4, or HER4. The overall amino acid identity between these proteins is about 50%. Caenorhabditis elegans and Drosophila melanogaster contain only one gene each encoding EGFR orthologues, called Let-23 and DER respectively. The different members of the EGFR family share conserved structural features that distinguish them from other RTKs. All are type Ia transmembrane proteins consisting of an extracellular ligand-binding domain, a single membrane-spanning domain and a cytoplasmic protein tyrosine kinase domain (Figure 1 ).
The most outstanding feature of the glycosylated extracellular domain of these receptors is the presence of conserved cysteine-rich clusters, which comprise the ligand-binding domain. All ErbB proteins contain two cysteine-rich domains, CRI and CRII, whereas their invertebrate counterparts, Let-23 and DER, have an additional cysteine-rich motif.
Within the cytoplasmic region three conserved sequence domains can be recognized. The juxtamembrane region is required for feedback attenuation by protein kinase C (PKC). It is followed by the tyrosine kinase domain -a Src homology domain 1, SH1 (Figure 1 ). This is the most conserved region among the EGFR protein familyexcept in ErbB3 -and it mediates auto-phosphorylation of the carboxyterminal tail on six tyrosine residues. The degree of evolutionary conservation is significantly reduced in the carboxy-terminal tail following the kinase domain. Nevertheless, the very carboxy-terminal tails of all EGFR molecules have important regulatory functions. The six tyrosine autophosphorylation sites are all located in the non-catalytic tail of the receptors. Phosphorylated tyrosine residues of the EGFR Finally, it has been noted that receptor downregulation can also be affected by sorting in the early endosomal compartment. For example it appears that in contrast to EGF, transforming growth factor-α (TGF-α) bound to the EGFR can already dissociate from the receptor in the early endosomal compartment leading to EGFR recycling as compared to the lysosomal degradation of EGF-bound receptors.
EGFR function
The ubiquitously expressed EGFR is a pleiotropic signal transducer and fulfills multiple roles during cell fate determination, differentiation, proliferation and apoptosis. The ErbB1 protein is a prototype of the EGFR family and its identification provided one of the first links between an activated oncogene and the development of cancer. ErbB1 is homologous to the product of the viral oncogene v-erbB, which encodes a truncated EGF receptor lacking the extracellular EGF-binding domain. In a large number of tumors the expression status of ErbB1 is also altered, due to overexpression or mutation. Because of its oncogenic potential, ErbB1 has been used as a prognostic marker for many years.
The first evidence of the crucial role of EGFR in cell differentiation during vertebrate development stems from EGF injection experiments 24 years ago. Injected mice showed precocious eye opening and tooth eruption. The fundamental role of EGFR in development has since been supported by numerous genetic studies. Null mutations in the individual ErbB loci are all embryonic lethal at day 10.5-13.5 p.c. and induce overlapping but not identical defects in multiple organs including brain, skin, lung, heart and eye.
C. elegans and Drosophila have served as useful model systems for studying the signaling processes triggered by the EGF receptor. As reflected by the many designations given to mutant alleles -faint little ball, torpedo and Ellipse -the Drosophila EGFR homologue, DER, is required at multiple times during fly development. Its requirement during axis determination and cell fate decisions during embryonic and imaginal disc development as well as during oogenesis formed the basis for several genetic studies that led to the identification of conserved signaling cassettes. In addition, genetic analyses have unraveled numerous regulatory mechanisms for EGFR activity and provided new insights into fundamental principles of animal development and cancer.
Downstream of EGFR
Studies on EGFR signaling in both vertebrates and invertebrates have converged on several evolutionarily conserved signaling cassettes that are required to transmit the signal from the receptor to the nucleus or to the cytoplasm (Figure 2) exchange of GTP for GDP on the small G-protein Ras. Subsequently activated Ras stimulates the MAP kinase pathway to promote cell proliferation.
In addition to the MAP kinase pathway, PLCγ and phosphatidylinositol 3-kinase -PI 3-kinase -are able to transduce EGFR activity. PLCγ activates second messenger systems which are required for enhanced cell motility. In this context PKC is activated and phosphorylates T654 in the juxtamembrane domain of the EGFR. This leads to a preferential disruption of the Ras-MAP kinase pathway and further biases the response to EGFR activation towards cell motility. PI 3-kinase regulates a number of downstream signaling components. For example, the PI 3-kinase-induced generation of H 2 O 2 blocks the activity of the inhibitory tyrosine protein phosphatase that would otherwise terminate EGFR activation. The complexity of signaling is further increased by cross-talk between individual pathways. Ras is able to regulate PI 3-kinase activity, and PLCγ can indirectly regulate Ras.
EGFR ligands
The number of ligands that can activate the ErbB family has increased during evolution. In C. elegans there is a single ligand, in Drosophila there are four and in mammals more than a dozen ligands have been identified. Generally, the cysteine-rich domains of the EGFR family members facilitate the binding of a diverse family of extracellular ligands such as TGF-α, EGF or Neuregulins, all of which contain a single EGF-like motif in their extracellular domain.
Six ligands are known to activate the EGFR: TGF-α, EGF, Amphiregulin, heparin-binding EGF-like growth factor, Betacellulin and Epiregulin. However no ligand is known for ErbB2. ErbB3 and ErbB4 bind to Neuregulins -a diverse family of more than fifteen proteins, all generated from a single gene. ErbB3 has no kinase activity and thus acts as a regulatory receptor.
Binding of EGF to EGFR favors dimerization of the receptor to form a complex containing two molecules of ligand and two molecules of receptor. The EGFR can also form heterodimers with ErbB2, which has a reduced internalization capacity compared with EGFR. This decreases EGFR downregulation and thus prolongs signaling from the EGFR.
EGFR ligands include both secreted molecules as well as 
EGFR antagonists
Inhibitory signaling is an important way of fine tuning EGFR activity to enable a cell to discriminate between short and prolonged exposure to signaling molecules. Over the last few years a number of different mechanisms have been shown to abrogate receptor activity (Figure 3) In summary, EGFR signaling appears to be integrated in a complex regulatory network linking extracellular signals to the cytoplasm and the nucleus. In the last decade the modulation of EGFR activity by negative regulators has become more and more evident. Now the picture is getting even more complicated by the fact that differential trafficking of activated EGFR may lead to different cellular responses. Further studies may not only help to increase our understanding of the role of EGFR signaling in the developing animal, they may ultimately lead to the development of efficient anticancer therapeutics.
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